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Summary The sensitivity of 7 human non-small cell lung cancer cell lines to each of 7 cytotoxic drugs was
determined. None of the cell lines used in these experiments had been previously exposed to cytotoxic drugs in
vitro. A pattern of cross-resistance (P<0.05) between the drugs adriamycin (ADR), vincristine (VC) and
etoposide (VP16) was noted similar to that seen in other models. The calcium antagonist verapamil (6.6,pM)
was shown to increase sensitivity (up to 29-fold) to ADR, VC or VP16 in 5 cell lines. For 2 of the cell lines
(A549 and WIL) 2.2jM verapamil increased VP16 cytotoxicity (up to 4-fold). Drug accumulation studies in 2
cell lines (A549 and SK-MES-1) showed that 6.6 jiM verapamil increased intracellular levels of VC up to 4-
fold with the greatest increase seen in the cell line (SK-MES-1) for which verapamil produced the greatest
increase in cytotoxicity (10-fold). For ADR and VP16 increases in drug accumulation were smaller (up to 1.6-
fold). Our data support a potential clinical role for verapamil in overcoming cytotoxic drug resistance in
human lung cancer.
Many of the experimental models of drug resistance rely on
the development of resistance in vitro through growth of cells
in drug-containing medium or in vivo through treatment of
mice bearing ascites or subcutaneous tumours. While these
models have the advantage that they produce sensitive and
resistant sublines of the same cell line the general relevance
of these models to clinical drug resistance is yet to be
established. In particular, using these models, cross-resistance
between anthracyclines, vinca alkaloids, VP16 and antibiotics
is often observed (see Discussion). Since certain therapeutic
strategies (e.g. the use of calcium antagonists; Tsuruo et al.,
1981) have been shown to be effective in overcoming this
resistance, the demonstration of a similar pattern of cross
resistance in human tumour cell lines which have not been
exposed to cytotoxic drugs in the laboratory would suggest
that clinical trials employing similar strategies might be
justified.
In this paper we use the term inherent resistance to
describe resistance that has not been induced by exposure to
cytotoxic drugs in experimental animals or in vitro.
For the drugs adriamycin (ADR) and vincristine (VC)
Tsuruo et al. (1983a,b) have shown that the inherent resis-
tance of both human haemopoietic and murine tumour lines
can be circumvented by the calcium antagonist verapamil.
Merry et al. (1986a) have also shown that inherent resistance
to ADR in human glioma cell lines can be overcome by
verapamil and that this is associated with increased intra-
cellular drug levels. Similar results have also been obtained
by Rogan et al. (1984) using human ovarian cancer cell lines.
In this paper we present data on the cross-sensitivity of a
panel of human non-small cell lung cancer cell lines to some
commonly-used cytotoxic drugs. We also report data on the
use of verapamil as a means of circumventing resistance in
human lung cancer which suggest that clinical studies
employing this approach may be justified.
Materials and methods
Seven established human non-small cell lung cancer cell lines
were used in this study. Their sources, pathological details
and (where available) the treatment undergone by the patient
prior to the establishment of the cell line are shown in
Table I. All cell lines grew as monolayer cultures.
The standard growth medium consisted of a mixture of
equal volumes of Ham's FIO and Dulbecco's Modified
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Eagle's Medium supplemented with 10% foetal calf serum
and with a gas phase of 2% CO2. In some cases this
medium was also supplemented with 50jigml-' gentamycin
sulphate.
The drugs used in this study were adriamycin (ADR,
Farmitalia Carlo Erba Ltd, Barnet, Herts, UK), actinomycin
D (AD, trade name Lyovac Cosmegen, Merk Sharp and
Dohme International, Rahway, NJ, USA), vincristine (VC,
trade name Oncovin, Eli Lilly and Co Ltd, Basingstoke,
UK), VP16 (etoposide, VP16-213, trade name Vepesid,
Bristol Myers Pharmaceuticals, Slough, UK), L-penylalanine
mustard (L-PAM, melphalan, trade name Alkeran, The
Wellcome Foundation Ltd, London, UK), mitomycin C
(MC, Kyowa Hakko Kogyo Co Ltd, Tokyo, Japan), 5-
fluorouracil (5FU, Roche Products Ltd, Welwyn Garden
City, Herts, UK) and verapamil (trade name Cordilox IV,
Abbot Laboratories Ltd, Queenborough, Kent, UK). The
drugs were solubilised according to the manufacturers'
instructions for injection and then stored as frozen aliquots
at -20°C until required (generally no longer than 2 months
after freezing). In the case of L-PAM care was taken to
ensure these operations were carried out within 30min
because of the instability of the drug in solution. L-4,5-[3H]-
leucine, [14-14C]ADR and [G-3H]VC were obtained from
Amersham International Plc (Amersham, Bucks, UK). [G-
3H]-VP16 was prepared as a custom synthesis (Amersham
International Plc) by tritium labelling a sample of VP16
powder (Bristol-Myers Pharmaceuticals). The final product
was purified in our laboratories by thin layer chromato-
graphy. 3H-leucine and 3H-VC were stored according to the
manufacturers' instructions. 14C-ADR and 3H-VP16 were
stored in methanolic solution at -20°C.
Cytotoxicity assay
The method used has been described previously (Merry et
al., 1984). Briefly, exponentially growing cultures in 96-well
Linbro microtitration plates were treated with serial dilutions
of drug (or drug combined with verapamil) for 72 h (with
drug replacement at 24 and 48h), followed by a recovery
period in the absence of drug of 120h (with medium
replacement at 72 and 96h). Viability of the cultures was
then assessed as the incorporation of [3H]-leucine into the
trichloroacetic acid-insoluble fraction of the cells. The incor-
poration was expressed as a percentage of control cultures
and the concentration of drug that inhibited protein
synthesis by 50% (ID50) determined. Cell counts (model ZB1
Coulter counter) of trypsinised replicate cultures were used
to determine population doubling time and to ensure that
c
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Table I Non-small cell lung cancer cell lines
Prior
clinical
Cell linle Pathologv Source treatnient
Calu-3 Adenocarcinoma American Type Culture Collection, USA Yesa
NCI-H23 Adenocarcinoma National Cancer Institute, USA None
NCI-H 125 Adenocarcinoma National Cancer Institute, USA None
WIL Adenocarcinoma Ludwig Institute, Sutton, UK Not reported
L-DAN Squamous carcinoma Medical Oncology, Glasgow, UK None
SK-MES-1 Squamous carcinoma American Type Culture Collection, USA Not reported
A549 Bronchiolo-alveolar American Type Culture Collection, USA Not reported
carcinoma
aCytotoxan, bleomycin, adriamycin.
control cultures remained in exponential growth throughout
the period of the experiment. In all experiments the period of
drug exposure (72 h) exceeded one population doubling time.
Drug uptake assaY'
The method used has been described previously (Merry et
al., 1986a). Briefly, 7.9 x 104 exponentially growing cells (105
cells cm -2) were seeded into 10 mm diameter soda glass
specimen tubes. After 72 h the cell monolayer was washed
and 0.2 ml of Hanks' balanced salts solution (adjusted to
pH 7.4) supplemented with glucose (6.1 mm final concen-
tration), MEM vitamins (Gibco Ltd, Paisley, UK), 4.5mM
NaHCO3, 6.6jM verapamil (in some cases) and lpCi ml-'
radiolabelled drug (ADR, VC or VP16). The final concen-
trations of ADR, VC and VP16 were 20pM, 0.13pM and
1.OpM respectively. Replicate tubes (4 per time point) were
then incubated at 37 C for 0, 30, 60 or 90 min before the cell
monolayer was washed with phosphate-buffered saline (0'C)
and a further 0.2 ml of drug-free Hanks' balanced salts
solution (supplemented as above and without verapamil) was
added. After a further incubation (30min, 37 C) unbound
dr-ug was determined using liquid scintallation counting as
the amount of radioactivity released into the supernatant
medium. Bound cIrug was determined by counting the
residual radioactivity of the washed, solubilised cell mono-
layer. In all experiments cell counts (model ZB1 Coulter
counter) from replicate tubes were used to express the results
as pmol drug taken up 10 -6 cells.
Results
Dr-ug sensitivity, e.xperiments
Table II shows the results of our drug sensitivity experiments.
Where duplicate determinations were carried out the range
of the results obtained are shown in the table. All replicate
determinations of ID50 fell within a 2.5-fold range.
Table III shows the cell lines ranked in order of sensitivity
of the cytotoxic drugs. In the case of duplicate deter-
Table III Drug sensitivity of NSCLC cell lines - ranked from most
sensitive (1) to most resistant (7)
Cell line ADR AD VC VP16 L-PAM MC 5FU
NCI-H23
Calu-3
NCI-H125
SK-MES-1
L-DAN
WIL
A549
2
3
4
S
6
7
3
2
7
S
6
4
2
6
4
3
7
5
2
7
4
5
3
6
2
3
4
5
7
6
2
6
4
3
7
3
2
1
7
5
6
4
minations the mean of the results was used to assign ranking
position. Statistical analysis of these data was carried out
using Kendall's coefficient of concordance (W) (Siegel, 1956).
The null hypothesis is that there is no correlation between
the ranking of sensitivity of the 7 cell lines. The value of W
for the whole table is 0.46 (P<0.01). Although this value is
highly significant, it can be increased to 0.60 by the
exclusion of L-PAM, MC and 5FU from the calculations.
These results indicate a pattern of cross-resistance between
the drugs ADR, AD, VC and VP16.
Effects of verapamnil on dcrug sensitivity
Table IV shows the effect of 6.6pM verapamil (added during
the period of cytotoxic drug treatment only) on ADR, VC
and VP16 sensitivity. Only 5 of the 7 cell lines were included
in this study since 6.6uM verapamil was found to be
appreciably toxic to NCI-H23 and Calu-3 (Table II). Where
duplicate experiments were carried out, the range of results is
shown. In these cases the variability of the results was
always less than 2.3-fold.
In 10 out of 15 cases (i.e. 3 drugs and 5 cell lines) Table IV
shows an increase in cytotoxicity produced by this non-
cytotoxic concentration of verapamil. This enhancement par-
ticularly in the case of ADR and VC is most pronounced
in those cell lines which were most resistant to drug alone,
i.e. WIL, A549 and L-DAN in the case of ADR; WIL,
NCI-H125, A549 and SK-MES-l in the case of VC.
Table II Cytotoxicity Data
Drug ID50
ADR AD VC VPJ6 L-PAM MC 5FU Vertapamil
Cell litle (X 10 9 M) (XIO- 10 M) (X 10 9W) (XO 8 M) ((X l-IO M) (X /() I M) (X1o 7M) (X 10 6 M)
NCI-H23 0.002-0.005 9.3 1.9 33 0.8-2.0 79 8 4.5
Calu-3 2.7 20 1.6 2.3 7.8 20 7.4 1.0
NCI-H 125 9.0 12 40-40 381 0.4 17 3.8-3.8 60
SK-MES-1 48-53 60 13-22 81-120 24 100 86 >55
L-DAN 34-70 50 17-17 92-110 84 60 42 >55
WIL 168 55 136 70-83 100 30 69 >55
A549 204-228 20-40 27-28 360 87 200 15 >55CIRCUMVENTION OF DRUG RESISTANCE BY VERAPAMIL 403
Table IV Increase in drug sensitivity produced by 6.6/iM verapamil
Cell line ADR VC VPJ6
NCI-H125 x 0.8a x 25.9-x 32.0 x 2.5
SK-MES-1 x 2.7- x 5.3 x 10.0 x 1.0
L-DAN x2.4-xS.0 x 1.1 x l.1-x 1.3
WIL x 8.4 x 2.6- x 4.0 x 11.0-x 13.9
A549 x2.1-x4.8 x5.2-x5.4 x5.3
'Fold change in ID5.
The effect of 2.2JiM and 0.7juM verapamil on ADR, VC
and VP16 cytotoxicity for the cell lines WIL and A459 was
also determined. These cell lines were chosen for this study
since an increase in sensitivity to all 3 cytotoxic drugs was
noted by 6.6/IM verapamil. Duplicate determinations were
carried out in all cases and the variability of the duplicates
was always less than 1.7-fold.
Verapamil at 2.2pM increased VP16 cytotoxicity for both
WIL (4.0-fold change in ID50) and A549 (3.3-fold change in
ID50) i.e. 32% (WIL) and 62% (A549) of that produced by
6.6IIM verapamil. In no other case was an increase in
sensitivity noted (data not shown).
Drug uptake experiments
In preliminary experiments with each of the drug combi-
nations and using identical conditions to those of the drug
uptake studies, cell viability (as determined by trypan blue
exclusion) and cell loss from the monolayer (as determined
by counting cell number in representative microscope fields)
were reduced by <5% for both A549 and SK-MES-1 (data
not shown).
In the drug uptake studies unbound drug was determined
as that released during a 30min incubation in glucose-
containing medium. In control experiments (for each drug or
drug combination) release of radioactivity under these con-
ditions was shown to be initially rapid followed by a slower
(apparently linear) release (data not shown). The initial
phase of drug release reached completion at 30min.
Figure I shows the effect of 6.6/tiM verapamil on the
uptake of VC by SK-MES-1. The general shape of the
curves are typical of those obtained for all three drugs
(ADR, VC and VP16) in both cell lines (A549 and SK-MES-
1). In all cases uptake of unbound drug was close to plateau
levels at 30min (both in the absence and presence of
verapamil), while levels of bound drug in the presence of
verapamil were apparently still rising at 90min. The data of
the drug uptake experiments are shown in Table V. For
ADR, VC and VP16 respectively A549 is 4.3, 1.6 and 3.6-
fold more resistant than SK-MES-1 (data taken from Table
II). The ratios (A549:SK-MES-1) of total drug levels at
90 min are however 0.8, 1.3 and 1.7 in the absence of
verapamil for ADR, VC and VP16 respectively.
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Figure I Vincristine uptake by the cell line SK-MES-l. (a)
Unbound drug; (b) bound drug. In the presence (0) and absence
(0) of 6.6pM verapamil. All experiments were carried out at
37 C using Hanks' balanced salt solution supplemented with
glucose (6.1 mM final concentration), MEM vitamines and
0.13 yM 3H-vincristine. Error bars indicate mean + s.e. Error
bars are omitted when their range would be smaller than the size
of the symbol used to indicate mean value.
Table VI summarises the data obtained in the drug uptake
experiments and enables a comparison of this data with the
effect of verapamil on cytotoxicity. For VC verapamil pro-
duced major increases in both cytotoxicity and drug accumu-
lation. Furthermore for SK-MES-1 the increases produced
by verapamil on cytotoxicity, drug accumulation and drug
Table V Effect of 6.6pM verapamil on drug accumulation
Drug accumulation at 90min
(pmol10-6cells)
Cell line ADR VC VPJ6
A549 -Verapamil Unbound 36.3 +0.8 a 9.0+0.5 12.4+0.3
Bound 61.6+2.3 11.0+0.1 9.8+0.1
+Verapamil Unbound 38.0+0.7 20.0+0.6 21.2 +0.8
Bound 78.7 +2.7 28.3 +0.9 14.8 +0.2
SK-MES-1 -Verapamil Unbound 41.2+3.2 7.2+0.5 6.8+0.3
Bound 85.5+ 10.1 8.4+0.3 7.3+0.1
+Verapamil Unbound 47.3 +2.8 23.5+0.5 8.8+0.3
Bound 117.0+ 13.1 44.6+1.2 9.8+0.2
"Mean +s.e. (n =4).
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Table VI Comparison of the effects of 6.6pM verapamil on drug
sensitivity and drug accumulation
Cell line ADR VC VP16
A549 Sensitivity x 3.54 x 5.3 x 5.3
Transport x 1.2b x 2.4 x 1.6
Binding x 1.2c x 1.2 x 0.9
SK-MES-I Sensitivity x4.0 x 10.0 x 1.0
Transport x 1.3 x4.4 x 1.3
Binding x 1.2 x 1.6 x 1.0
aFold change in ID50 (where duplicate determinations were made,
the figure given in the mean value); bFold change in total drug
accumulation (bound plus unbound) at 90min; cFold change in ratio
bound:unbound drug at 90min.
binding were all -2-fold those seen in A549. For ADR and
VP16 the direct relationship between drug accumulation and
sensitivity was not as clear since the increases in drug
accumulation and binding were relatively small. For ADR,
verapamil did however, produce increases in drug uptake,
drug binding, and drug sensitivity in both cell lines. For
VP16 in the case of cell line A549 the increase in cytotoxicity
produced by -verapamil is associated with increased drug
uptake and drug binding. Increased drug uptake was also
seen in the cell line SK-MES-1 where no effect of verapamil
on cytotoxicity was noted. In both A549 and SK-MES-1
verapamil did not increase the ratio bound:unbound VP16.
Discussion
We have examined the sensitivity of a panel of 7 non-small
cell lung cancer cell lines to 7 cytotoxic drugs. None of the
cell lines (4 adenocarcinomas, 2 squamous carcinomas and 1
bronchiolo-alveolar carcinoma) had been exposed to cyto-
toxic drugs in vitro. A pattern of cross-resistance (termed
pleiotropic drug resistance, PDR) to ADR, VC and VP16
was found similar to that described in animal models (for
review see Kaye & Merry, 1985). PDR has also been
described in human haemopoietic tumour cell lines (Beck,
1983), human glioma cell lines (Merry et al., 1984) and
human small cell lung cancer cell lines (Shoemaker et al.,
1983). The cross-resistance data described here thus provide
further evidence that PDR may be a general phenomenon in
cell lines derived from human tumours, although the clinical
relevance of PDR still remains to be established.
PDR has two important characteristics; (a) altered
membrane transport (possibly enhanced drug efflux) has
been postulated as the major factor underlying this resistance
and (b) in some experimental models PDR has been circum-
vented by calcium antagonists such as verapamil (for review
see Chabner et al., 1983).
We have studied the effect of 6.6 IM verapamil on the
cytotoxicity of ADR, VC and VP16 in 5 cell lines. This dose
of verapamil has been previously used to potentiate the
effects of ADR and VC in human haemopoietic tumour cell
lines (Tsuruo et al., 1983a) and of ADR in human ovarian
tumour cell lines (Rogan et al., 1984). This non-cytotoxic
concentration of verapamil was able to potentiate the effect
of the 3 cytotoxic drugs in some of the cell lines (up to 29-
fold) with, particularly for ADR and VP16, potentiation in
the most resistant cell lines.
Plasma levels of up to 1OpM verapamil may be achieved
clinically by i.v. infusion (Ozols et al., 1984), but these are
associated with significant cardiovascular toxicity. Levels of
1-3 JM verapamil may be achieved in cancer patients using a
daily oral dose of 480mg per day (Kerr et al., 1986), with
minimal toxicity. In order to assess the efficacy of these
lower dose levels we investigated the effect of 2.2pM and
0.7pM verapamil on ADR, VC and VP16 cytotoxicity using
2 cell lines (A549 and WIL) in which 6.6pM verapamil
potentiated the effect of all 3 drugs.
Verpamil did not enhance sensitivity to ADR and VC at
these concentrations, but we did observe increased VP16
cytotoxicity at 2.2pM verapamil in both cell lines. We have
confirmed this observation in vivo in separate experiments
which indicate that verapamil (at murine plasma levels of
1.6pM) is able to increase the sensitivity of WIL xenografts
to VP16 (Merry et al., 1986b).
In the clinical trial of Kerr et al. (1986) patients with small
cell lung cancer were treated with 4-day chemotherapy and 5
days of oral verapamil (480mgday-1) and plasma levels of
1.5 kM verapamil were obtained. In addition, levels of the
major metabolite norverapamil were measured at 1.5p1M.
Our preliminary laboratory studies investigating the
biological activity of norverapamil in circumventing drug
resistance indicate that it has approximately equal activity to
verapamil (unpublished data).
Using two cell lines (A549 and SK-MES-1) we have also
investigated the effects of 6.6JIM verapamil on ADR, VC
and VP16 accumulation and binding. It was a common
finding for both cell lines with ADR and VC that verapamil
increased the ratio of bound:unbound drug. These data are
consistent with the observations of Hindenberg et al. (1987)
that, for ADR, verapamil displaces drug from the
hydrophobic into the hydrophilic compartment of the cell.
Drug within the hydrophilic compartment is potentially less
readily released than lipid associated drug. Furthermore a
recent study by Cornwell et al. (1986) has shown that
verapamil is able to directly modulate the vinblastine photo-
affinity labelling of a 170 kDa glycoprotein in membrane
vesicles from multidrug resistant cells.
For VC a clear relationship emerged between the effects of
verapamil on sensitivity, drug accumulation and binding
(Table VI). This suggests that (at least in these two cell lines)
the major mechanism by which verapamil increases cyto-
toxicity to VC may be by influencing drug transport and/or
binding. For ADR and VP16 smaller increases in drug
accumulation were seen. These increases are associated with
increased sensitivity to ADR (in both cell lines) and VP16
(in A549). In SK-MES-1, however, verapamil increased
VP16 accumulation, but had no effect on cytotoxicity. Drug
accumulation may not be rate-limiting for cytotoxicity in this
particular case due to saturation of the intracellular binding
sites at which VP16 acts.
In previous study (Merry et al., 1986a) using human
glioma cell lines verapamil (13 JM) produced increases in
ADR uptake, binding and sensitivity in resistant cell lines.
The increases were of equivalent size to those seen in this
study.
Verapamil might also be enhancing drug sensitivity by a
mechanism or mechanisms unrelated to total intracellular
drug accumulation and binding. The presence of additional
mechanisms of resistance is indicated by the observation that
for VC and VP16 the drug sensitivity data (Table II) show
A549 to be respectively 1.6 and 3.6-fold more resistant than
SK-MES-1 while in the drug uptake experiments (Table VI)
accumulation of drug was greatest in A549.
While in this study reduced ADR accumulation was noted
in A549 (resistant) compared to SK-MES-1 (sensitive) a lack
of correlation between sensitivity and uptake has been
reported for rodent pancreatic carcinoma cell lines (Chang &
Gregory, 1985) and human glioma cell lines (Merry et al.,
1986a). Kessel and Wilbarding (1985) have also reported that
differences in ADR sensitivity between 2 sublines of P388
muring leukaemia could not be totally accounted for by
differences in drug accumulation.
It is also recognised that clinical resistance to cytotoxic
drugs may occur in tumours by mechanisms not involving
biochemical changes within individual tumour cells.
Examples of such mechanisms might be a reduction in
tumour blood supply (leading to decreased entry of cytotoxic
drug into the tumour) or increased cytotoxic drug degra-
dation at a site other than the tumour (e.g. the liver). Such
factors may also occur in combination with cellular factors.
Nevertheless studies in several human solid tumour types
have shown that the occurrence of drug resistance in the
clinic is associated with the presence of drug-resistant clono-
genic cells in biopsy specimens (Salmon, 1984). These obser-CIRCUMVENTION OF DRUG RESISTANCE BY VERAPAMIL 405
vations indicate that resistance due to cellular mechanisms
may be an important factor in clinically observed drug
resistance.
In conclusion our data form part of a growing body of
evidence that resistance to ADR, VC and VP16 may be
multifactoral in nature, but suggest that (particularly for VC)
changes in drug transport may be involved in resistance to
these drugs in human solid tumours.
We have shown that verapamil is able to circumvent drug
resistance in some human non-small cell lung cancer cell
lines and that this effect (for VP16) can be demonstrated at
clinically achievable plasma concentrations. Clinical studies
using the approach of cytotoxic drug enhancement by non-
cytotoxic membrane-active compounds such as verapamil
appear to be justified.
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